Prostate cancer study reveals differential molecule

March 2009
Medical Device Daily;3/23/2009, Vol. 13 Issue 54, p3
The article discusses a study from the National Cancer Institute's (NCI) Cancer Biomarkers Research Group which suggests that a molecule produced by the body's metabolism could be used to differentiate between benign prostate tissue versus localized and metastatic prostate cancer. The researchers also found that the molecule called sarcosine may be associated with invasiveness and aggresiveness of prostate cancer. The group performed analyses of laboratory-grown cells to investigate the role of sarcosine in prostate cancer progression.


Related Articles

  • Molecular sampling of prostate cancer: a dilemma for predicting disease progression. Sboner, Andrea; Demichelis, Francesca; Calza, Stefano; Pawitan, Yudi; Setlur, Sunita R.; Hoshida, Yujin; Perner, Sven; Adami, Hans-Olov; Fall, Katja; Mucci, Lorelei A.; Kantoff, Philip W.; Stampfer, Meir; Andersson, Swen-Olof; Varenhorst, Eberhard; Johansson, Jan-Erik; Gerstein, Mark B.; Golub, Todd R.; Rubin, Mark A.; AndrĂ©n, Ove // BMC Medical Genomics;2010, Vol. 3, p8 

    Background: Current prostate cancer prognostic models are based on pre-treatment prostate specific antigen (PSA) levels, biopsy Gleason score, and clinical staging but in practice are inadequate to accurately predict disease progression. Hence, we sought to develop a molecular panel for prostate...

  • Prostate study reveals differential molecule.  // Medical Device Daily;3/24/2009, Vol. 13 Issue 55, p4 

    The article discusses a study which investigated a molecule produced by the body's metabolism. The researchers found that the molecule could be used to differentiate between benign prostate tissue versus localized and metastatic prostate cancer. The molecule is called sarcosine and it was...

  • Volume-related Sequence of Tumor Distribution Pattern in Prostate Carcinoma: Importance of Posterior Midline Crossover in Predicting Tumor Volume, Extracapsular Extension, and Seminal Vesicle Invasion. Torlakovic, Goran; Torlakovic, Emina; Skovlund, Eva; Nesland, Jahn M.; Reith, Albrecht; Danielsen, Havard E. // Croatian Medical Journal;2005, Vol. 46 Issue 3, p429 

    Aim To evaluate intraprostatic distribution of prostate carcinoma as a function of increasing tumor size and its potential clinical relevance. Methods Forty-six prostates with different tumor extent were three dimensionally reconstructed and analyzed with emphasis on number of separate tumors...

  • Sequential maximum androgen blockade (MAB) in minimally symptomatic prostate cancer progressing after initial MAB: two case reports. Hingorani, Mohan; Dixit, Sanjay; Bashir, Fahim; Butt, Mohammad; Hawkyard, Simon; Khafagy, Richard; Robertson, Andrew // Cancer Biology & Medicine;Dec2014, Vol. 11 Issue 4, p277 

    The management of castrate-resistant prostate cancer progressing after maximum androgen blockade (MAB) has evolved in the last decade with the development of several novel therapeutic options. However, the initial therapeutic strategy in these patients usually involves withdrawal of...

  • AUTHOR'S REPLY. Takehiro Sejima // Central European Journal of Urology;2013, Vol. 66 Issue 2, p135 

    In this article the author comments about views on their article on discovering preoperative non-tumor related biomarkers which can easily be obtained by routine laboratory examination. The author says that delayed diagnostic procedure may be responsible for micro metastases progression of...

  • Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Crea, Francesco; Hurt, Elaine M.; Mathews, Lesley A.; Cabarcas, Stephanie M.; Lei Sun; Marquez, Victor E.; Danesi, Romano; Farrar, William L. // Molecular Cancer;2011, Vol. 10 Issue 1, p40 

    Background: Polycomb repressive complex 2 (PRC2) mediates gene silencing through histone H3K27 methylation. PRC2 components are over-expressed in metastatic prostate cancer (PC), and are required for cancer stem cell (CSC) self-renewal. 3-Dezaneplanocin-A (DZNeP) is an inhibitor of PRC2 with...

  • The bifunctional autophagic flux by 2-deoxyglucose to control survival or growth of prostate cancer cells. Jeong Yong Jeon; Seung Won Kim; Ki Cheong Park; Mijin Yun // BMC Cancer;9/8/2015, Vol. 15 Issue 1, p1 

    Background: Recent reports using metabolism regulating drugs showed that nutrient deprivation was an efficient tool to suppress cancer progression. In addition, autophagy control is emerging to prevent cancer cell survival. Autophagy breaks down the unnecessary cytoplasmic components into...

  • Performance evaluation of commercial miRNA expression array platforms. Sah, Sachin; McCall, Matthew N.; Eveleigh, Deepa; Wilson, Michael; Irizarry, Rafael A. // BMC Research Notes;2010, Vol. 3, p80 

    Background: microRNAs (miRNA) are short, endogenous transcripts that negatively regulate the expression of specific mRNA targets. The relative abundance of miRNAs is linked to function in vivo and miRNA expression patterns are potentially useful signatures for the development of diagnostic,...

  • Prognostic Significance of Pretreatment Plasma Fibrinogen and Platelet Levels in Patients with Early-Stage Cervical Cancer. Zhao, Kelei; Deng, Huan; Qin, Yan; Liao, Wenjun; Liang, Weijiang // Gynecologic & Obstetric Investigation;Jan2015, Vol. 79 Issue 1, p25 

    Background: Hyperfibrinogenaemia and thrombocytosis, which usually occur in cancer patients, have been shown to contribute to cancer cell growth, progression, and metastasis. The aims of the present study were to assess the prognostic significance of pretreatment plasma fibrinogen and platelet...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics